Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Dose-escalation Study of Radio- Labeled Antibody, FF-21101(90Y) for the Treatment of Advanced Cancer

Next Previous
Trial Profile

A Phase 1 Dose-escalation Study of Radio- Labeled Antibody, FF-21101(90Y) for the Treatment of Advanced Cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 15 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FF 21101 Y-90 (Primary)
  • Indications Advanced breast cancer; Carcinoma; Cholangiocarcinoma; Chondrosarcoma; Clear cell sarcoma; Colorectal cancer; Duodenal cancer; Fallopian tube cancer; Gastrointestinal cancer; Head and neck cancer; Leiomyosarcoma; Liposarcoma; Lung cancer; Neuroendocrine tumours; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Vulvovaginal cancer
  • Focus Adverse reactions; First in man
  • Sponsors FujiFilm Pharmaceuticals USA; Strategia Therapeutics

    • Most Recent Events

    • 05 Apr 2022 Status changed from active, no longer recruiting to completed.
    • 25 May 2021 Status changed from recruiting to active, no longer recruiting.
    • 17 Jan 2021 Results (n=31)presented at the 2021 Gastrointestinal Cancers Symposium
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top